Reviewer's report

Title: Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure

Version: 1 Date: 21 October 2011

Reviewer: paul mulder

Reviewer's report:

This study described the effect of the mineralocorticoid receptor antagonist spironolactone on pulmonary remodelling and right ventricular function in a rat model of congestive heart failure. The subject is timely and of great interest. The results obtained in this well-designed study clearly support the conclusion draw. However, some points need to be addressed.

Major Compulsory Revisions.

No major compulsory revisions

Minor Essential Revisions.

1. In the abstract of some abbreviations, i.e. RVSP, TAPSE and RVMPI, are not comprehensible for non-expert reader, and thus their meaning must be mentioned.

2. The second paragraph of the discussion section concerning the clinical (under)use eplerenone and spironolactone is somewhat out of scoop, and reduction of it’s length will highlight the main result of the manuscript.

3. Throughout the manuscript the use of the generic name spironolactone should be used instead of the trademark Aldactone.

4. Delete ++ in the 7th paragraph of the discussion section.

Discretionary Revisions.

1. Drug names do not need to start with a capital letter.

2. The manuscript deals with the implication of aldosterone on right ventricular remodelling and pulmonary function. It might be of interest to separate the data concerning left end right ventricles by presenting the all data concerning the right ventricle/respiratory function in table 1 and all data concerning the left ventricle in table 2.

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests